The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
May 14th 2024
Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.
TNFi Treatment did not Increase Incidence of Hematological Malignancies in Psoriatic Arthritis
Although the incidence rates were similar among those treated with TNFi and biologics-naïve patients, patients with psoriatic arthritis had a 35% increased risk when compared with the general population.
ACR Identifies an Ongoing Need to Increase Interest in Pediatric Rheumatology
Potential barriers to an interest in pediatric rheumatology include inadequate exposure and mentorship within these specialties, as well as long periods of required training and lower compensation for pediatric specialists.
Patient-Reported Outcomes Become More Involved in Treating, Managing Rheumatic Diseases in 2022
With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.
Program Highlights Importance of Patient Perspective in Hispanic Patients with Rheumatoid Arthritis
“We realize, looking at the literature and also our clinical experience, that there are significant health disparities that are well documented in literature in Latinx and Hispanic rheumatoid arthritis patients, including perceptions of increased pain, fatigue, higher risk for depression, and a history of other self-help and self-management programs,” Adena Batterman, MSW, LCSW, explained.
Denosumab Effectively Halts Erosive Progression of Hand Osteoarthritis
Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.